Takeda launches gastrointestinal drug Vedolizumab in India
Kynteles is used for the treatment of adult patients with moderate to severely active Ulcerative Colitis (UC) and Crohn's Disease (CD).;
New Delhi: Takeda India, part of the Takeda Pharmaceutical Company Limited has announced the expansion of its highly innovative portfolio for patients in the country with the launch of Kynteles (generic name: Vedolizumab) as part of its Gastrointestinal (GI) portfolio.
GI is Takeda's second therapeutic area in India after Rare Diseases (Haematology, Genetic Diseases, and Immunology).
Kynteles is used for the treatment of adult patients with moderate to severely active Ulcerative Colitis (UC) and Crohn's Disease (CD). Kynteles, more widely known as Entvyio, has shown favorable safety and efficacy results in treating patients suffering from moderate to severe IBD.
Speaking about the launch, Koki Sato, Country Head, Takeda India, said, "At Takeda, we are continuously working towards developing innovative medicines to considerably improve the quality of life of patients. The launch of our highly innovative GI portfolio is a testimony of our commitment to India and patients living with diseases like UC and CD. Patient access to Kynteles will further augment our vision of providing additional and innovative treatment options to HCPs treating UC and CD."
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.